
Please visit answersincme.com/BWG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses integrating clinical trial and real-world evidence into the use of newer-generation anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Review the role of different types of data in informing management of retinal diseases; Assess clinical trial data and real-world evidence supporting the use of newer-generation anti-VEGF agents for retinal diseases; and Propose treatment plans for the management of retinal diseases based on clinical trial data and real-world evidence.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation

Optimizing Real-World Management of Early Alzheimer’s Disease: Maintenance Therapy and Long-Term Evidence

Novel and Emerging Oral GLP-1 RAs: Advancing Personalized Care for Canadians With Type 2 Diabetes

Case-Based Guidance on Tailoring Treatment Selection for Menopause-Related VMS
Free AI-powered recaps of CME in Minutes: Education in Primary Care and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.